Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
TNF Pharmaceuticals, Inc. - Common Stock
(NQ:
TNFA
)
5.200
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about TNF Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Unusual volume stocks in Friday's session
↗
April 04, 2025
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via
Chartmill
What's going on in today's after hours session
↗
April 03, 2025
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
Tuesday's after hours session: top gainers and losers
↗
April 01, 2025
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
April 01, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
March 20, 2025
Via
Benzinga
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
March 17, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
What's going on in today's after hours session
↗
March 13, 2025
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
March 13, 2025
Via
Benzinga
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
March 05, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
Stay updated with the stocks that are on the move in today's after-hours session.
↗
February 28, 2025
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via
Chartmill
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
February 25, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
February 07, 2025
Via
Benzinga
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
January 29, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
January 23, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
January 21, 2025
Via
Benzinga
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
January 15, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
December 19, 2024
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
December 09, 2024
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
October 03, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
October 02, 2024
Via
Benzinga
TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
October 02, 2024
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
September 02, 2024
Via
Benzinga
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline
August 21, 2024
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNFA Stock Earnings: TNF Pharmaceuticals Reported Results for Q2 2024
↗
August 19, 2024
TNF Pharmaceuticals just reported results for the second quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
